AMENDMENTS TO THE CLAIMS

1 to 10. (Canceled)

11. (New) Method for the production of a stable injectable formulation of poorly soluble antineoplastic agents, wherein a formulation comprising the antineoplastic agent and a solvent and/or a solvent system, which optionally contains a solubilizing agent, is treated with a cation exchanger.

12. (New) Method as claimed in claim 11, wherein the antineoplastic agent is paclitaxel, camptothecine or teniposide.

13. (New) Method as claimed in claim 12, wherein the antineoplastic agent is paclitaxel.

14. (New) Method as claimed in claim 11, wherein the content of the active agent in the solution is 1 - 10 mg/ml.

15. (New) Method as claimed in claim 14, wherein the content of the active agent paclitaxel is 4-8 mg/ml.

16. (New) Method as claimed in claim 15, wherein the content of the active agent paclitaxel is 6 mg/ml.

17. (New) Method as claimed in claim 11, wherein as the solvent or solvent system with solubilizing agent are utilized ethanol, ethanol/polyoxyethylene castor oil, ethanol/polysorbate and ethanol/polyethylene glycol.

18. (New) Method as claimed in claim 17, wherein the content of ethanol in the solvent system ethanol/polyoxyethylene castor oil is 10 - 90 parts.

19. (New) Method as claimed in claim 17, wherein the content of ethanol in the solvent system ethanol/polysorbate is 40 - 60 parts.

20. (New) Method as claimed in claim 11, wherein as the cation exchanger an ion exchanger containing sulfonic acid groups or carboxylate groups is employed.

21. (New) Method as claimed in claim 11, wherein the quantity of the cation exchanger is 0.01 - 10% of the total batch.